Drug firms await India court decision on patent protection

03/27/2013 | Economic Times (India), The

Pharmaceutical companies are awaiting a decision from India's Supreme Court, due April 1, that could determine the state of intellectual property protection for branded drugs in India. The case involves whether an amended form of Novartis' cancer treatment Glivec, used to treat chronic myeloid leukemia, is entitled to patent protection against generic competitors. "Big Pharma is nervous because nothing has gone in their favour in the recent past," said pharmaceutical consultant Ajay Kumar Sharma.

View Full Article in:

Economic Times (India), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA